Glucose concentration assessment before noncardiac surgery may help clinicians predict the risk for postoperative myocardial injury in patients with and without diabetes.
Diagnostic thresholds for gestational diabetes should be adapted using local populations.
A full-nut dose lowered HbA1c and estimated cholesterol levels in LDL particles of a certain diameter.
This represents the prospective study confirming an independent relationship between cardiovascular mortality and oxidative DNA damage in type 2 diabetes.
Small changes in health behaviors were seen in partners of those newly diagnosed with diabetes.
Increased risk for heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction.
Investigators examined the outcomes of using various beta-blockers in patients with type 2 diabetes after a myocardial infarction.
Canagliflozin vs other SGLT2 inhibitors and non-SLGT2 inhibitors were examined for the risk for heart failure-related hospitalization and below the knee amputation.
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.
Women with preeclampsia or gestational hypertension during their first pregnancy were more likely to report increased rates of subsequent chronic hypertension, type 2 diabetes, and hypercholesterolemia compared with women who were normotensive.
High BMI, low physical activity levels, and frequent smoking and high genetic risk increased the risk for atrial fibrillation, coronary artery disease, hypertension, stroke, and diabetes.
Investigators examined gender differences in baseline characteristics and outcomes in patients with t2d and ASCVD.
Investigators examined the association between hypoglycemia and cardiovascular outcomes and death.
For this study, researchers conducted a randomized, double-blind, placebo-controlled Phase 2 trial (N=24) to assess the efficacy and safety of adding oral verapamil for 12 months to a standard insulin regimen in adults with recent-onset type 1 diabetes (age range: 18 to 45 years).
Obesity paradox was pronounced in current smokers and absent in never smokers with type 2 diabetes.
Investigators demonstrated that angina severity at baseline should be a less important aspect of the diagnostic and therapeutic algorithm.
Increased risk for diabetes seen in women but not men, and was slightly attenuated after adjustment for mediating factors.
Vascular disease mortality accounted for nearly half of all deaths in type 2 diabetes; now this rate has decreased.
Investigators examined the effect of intensified multifactorial intervention on the risk for heart failure-related hospitalization in patients with type 2 diabetes and microalbuminuria.
Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.
Investigators examined the relationship between the use of β-blockers and incidence of hypoglycemia and risk for mortality in hospitalized patients with diabetes.
Investigators conducted a meta-analysis to compare the efficacy of SGLT2i, DPP-4i, and GLP-1 agonists for reducing cardiovascular outcomes.
Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.
The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.
Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.
To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.
Investigators sought to determine whether methylglyoxal levels are associated with cardiovascular disease in type 2 diabetes.
Impaired global longitudinal strain and left ventricular hypertrophy may be predictive of incident heart failure in patients with asymptomatic type 2 diabetes.
Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.
The Cardiology Advisor Articles
- AHA/ACC: Updated Management Guidelines for Adult Congenital Heart Disease
- USPSTF Does Not Recommend Afib Screening in Asymptomatic Patients
- American Heart Association Urges Screen Time Limits for Youth
- Patient Connectivity Benefits Familial Chylomicronemia Syndrome
- FDA Approves First Drug Under the Competitive Generic Therapy Pathway
- Apixaban Lowers Bleeding Risk in Afib With End-Stage Kidney Disease
- Tricuspid Regurgitation Velocity Unreliable Indicator of Pulmonary Hypertension
- Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes
- The Challenge of Compassion in Modern Healthcare Settings
- Concomitant NSAID and Anticoagulant Use May Increase Stroke, Bleeding Risk in Afib
- Extreme Preterm Infants at Risk for Early Age High Blood Pressure
- Anemia Identified as Risk Factor for Contrast-Induced Acute Kidney Injury
- Case: Hypertensive Crisis Following Use of Armodafinil + MAOI
- Triple Combination Pill Can Improve Blood Pressure Control
- Labetalol Use Higher in Patients With Preeclampsia and Asthma